Thursday, November 14, 2024
HomeFundingSyantra Secures $4.9 Million in Series A-1 Funding

Syantra Secures $4.9 Million in Series A-1 Funding

Syantra, a privately held precision biotechnology company pioneering a platform to change the way cancer is detected and treated, announced that it has raised an additional $4.9 million Canadian Dollars in Series A-1 funding.

Syantra, a privately held precision biotechnology company pioneering a platform to change the way cancer is detected and treated, announced that it has raised an additional $4.9 million Canadian Dollars in Series A-1 funding.

Read also – Radiant Bio Raises $35 Million Series A Financing to Advance Therapeutic Pipeline

The funding, which comes from a collective of individuals introduced by CG Wealth Management, along with additional support from existing investors, will empower Syantra to fast-track clinical validation and commercialization of the first test on its patent-pending platform for early detection of breast cancer.

Read also – SpectraWAVE Raises $50 Million in Series B Funding Round

Syantra also announced the addition of Dr. Rick Mangat to its Board of Directors. Dr. Mangat brings over 20 years of experience as a medical device executive. Dr. Mangat co-founded NOVADAQ Technologies Inc. in 2000 and served as the company CEO until the company was acquired in September 2017.

These announcements follow recent related news wherein Cornell University and the University of Calgary (UC) received partnering awards from the U.S. Department of Defense (DoD) for a total of more than $2.4 million US Dollars to fund a three-year, 2,000 participant clinical study to expand work with Syantra’s early breast cancer detection blood test at six sites in the US and United Kingdom.

UC’s Kristina Rinker, PhD, a Syantra co-founder, is a partner principal investigator on the multinational project. The clinical study will evaluate the Syantra DX™ Breast Cancer test in new and diverse populations.

“We’re on the cusp of something transformative here, in both fulfilling the mission and furthering the growth of Syantra” said Rob Lozuk, CEO. “On the heels of the DoD project, this influx of support will empower Syantra to focus on the science that drives us forward, enabling the team to execute ongoing clinical studies and other efforts prior to ramping up commercialization in 2025.”

“The in-house R&D team, along with our select group of partners and investors, comprises forward-thinking scientific leaders who recognize that current detection methods can be ‘too little, too late,’ because, in the case of breast cancer, by the time a mammogram detected abnormality is biopsied, the cancer may have already established a firm foothold.”

About Syantra

Syantra was formed in 2016 by Dr. Tina Rinker, Dr. Ken Fuh, Dr. Randy Moore and Bob Shepherd. Syantra Inc. is a privately held, precision biotechnology company that’s changing the way cancer is detected and treated.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular